Literature DB >> 17917151

Markers in normal and cancer stem cells.

Thanemozhi G Natarajan1, Kevin T FitzGerald.   

Abstract

In an effort to better understand and address the challenges of cancer research and treatment, a new model of tumorigenesis is being developed - the cancer stem cell model. Building upon traditional concepts of cancer and stem cells, this model is intended to shed new light on the continued struggle with treatment issues such as tumor drug-resistance and recurrence. This review describes the cancer stem cell model with an emphasis on markers that represent the "stemness" phenotype. A thorough understanding of normal and cancer stem cells is necessary for a precise delineation of cancer stem cells. The objective of such an improved delineation is to develop targeted therapy for selective elimination of cancer stem cells with minimal toxicity to normal stem cells. Specific targeting of cancer stem cells has proved to be a significant challenge due to the commonality of many markers between normal and cancer stem cells. However, research in the area of cancer biomarkers is slowly, but steadily, progressing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917151     DOI: 10.3233/cbm-2007-34-506

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  11 in total

Review 1.  The intestinal stem cell.

Authors:  Nick Barker; Marc van de Wetering; Hans Clevers
Journal:  Genes Dev       Date:  2008-07-15       Impact factor: 11.361

2.  Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients.

Authors:  Alireza Mirzaei; Gholamreza Tavoosidana; Mohammad Hossein Modarressi; Afshin Abdi Rad; Mohammad Sadegh Fazeli; Reza Shirkoohi; Masoumeh Tavakoli-Yaraki; Zahra Madjd
Journal:  Tumour Biol       Date:  2015-01-29

3.  Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.

Authors:  Yang Jiang; Yan He; Hui Li; Hui-Ning Li; Lei Zhang; Wei Hu; Ya-Meng Sun; Fu-Lai Chen; Xiao-Ming Jin
Journal:  Gastric Cancer       Date:  2012-02-14       Impact factor: 7.370

Review 4.  Lung cancer stem cells and low-intensity laser irradiation: a potential future therapy?

Authors:  Anine M Crous; Heidi Abrahamse
Journal:  Stem Cell Res Ther       Date:  2013       Impact factor: 6.832

5.  A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?

Authors:  Alireza Mirzaei; Gholamreza Tavoosidana; Afshin Abdi Rad; Farhad Rezaei; Masoumeh Tavakoli-Yaraki; Azade Amini Kadijani; Ehsan Khalili; Zahra Madjd
Journal:  Tumour Biol       Date:  2015-09-17

Review 6.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

7.  Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.

Authors:  Yimao Zhang; John Laterra; Martin G Pomper
Journal:  Neoplasia       Date:  2009-01       Impact factor: 5.715

8.  NF-kappaΒ-inducing kinase regulates stem cell phenotype in breast cancer.

Authors:  Karla Vazquez-Santillan; Jorge Melendez-Zajgla; Luis Enrique Jimenez-Hernandez; Javier Gaytan-Cervantes; Laura Muñoz-Galindo; Patricia Piña-Sanchez; Gustavo Martinez-Ruiz; Javier Torres; Patricia Garcia-Lopez; Carolina Gonzalez-Torres; Victor Ruiz; Federico Avila-Moreno; Marco Velasco-Velazquez; Mayra Perez-Tapia; Vilma Maldonado
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

9.  Phenotypic heterogeneity in modeling cancer evolution.

Authors:  Ali Mahdipour-Shirayeh; Kamran Kaveh; Mohammad Kohandel; Sivabal Sivaloganathan
Journal:  PLoS One       Date:  2017-10-30       Impact factor: 3.240

10.  The Roles of Dietary PPARgamma Ligands for Metastasis in Colorectal Cancer.

Authors:  Hiroki Kuniyasu
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.